全文获取类型
收费全文 | 13463篇 |
免费 | 884篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 139篇 |
儿科学 | 494篇 |
妇产科学 | 363篇 |
基础医学 | 2010篇 |
口腔科学 | 199篇 |
临床医学 | 1620篇 |
内科学 | 2443篇 |
皮肤病学 | 323篇 |
神经病学 | 1642篇 |
特种医学 | 312篇 |
外科学 | 1321篇 |
综合类 | 67篇 |
一般理论 | 13篇 |
预防医学 | 1091篇 |
眼科学 | 234篇 |
药学 | 861篇 |
中国医学 | 17篇 |
肿瘤学 | 1235篇 |
出版年
2023年 | 99篇 |
2022年 | 183篇 |
2021年 | 302篇 |
2020年 | 246篇 |
2019年 | 324篇 |
2018年 | 366篇 |
2017年 | 307篇 |
2016年 | 371篇 |
2015年 | 409篇 |
2014年 | 502篇 |
2013年 | 708篇 |
2012年 | 1058篇 |
2011年 | 1022篇 |
2010年 | 624篇 |
2009年 | 555篇 |
2008年 | 860篇 |
2007年 | 892篇 |
2006年 | 874篇 |
2005年 | 833篇 |
2004年 | 762篇 |
2003年 | 705篇 |
2002年 | 672篇 |
2001年 | 85篇 |
2000年 | 49篇 |
1999年 | 106篇 |
1998年 | 158篇 |
1997年 | 126篇 |
1996年 | 97篇 |
1995年 | 103篇 |
1994年 | 62篇 |
1993年 | 75篇 |
1992年 | 45篇 |
1991年 | 53篇 |
1990年 | 44篇 |
1989年 | 25篇 |
1988年 | 34篇 |
1987年 | 22篇 |
1986年 | 27篇 |
1985年 | 28篇 |
1984年 | 28篇 |
1983年 | 34篇 |
1982年 | 42篇 |
1981年 | 23篇 |
1980年 | 33篇 |
1979年 | 28篇 |
1978年 | 15篇 |
1977年 | 20篇 |
1976年 | 27篇 |
1974年 | 20篇 |
1969年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
Welmoed van Loon Heike Rssig Susen Burock Jrg Hofmann Julian Bernhard Elisabeth Linzbach Domenika Pettenkofer Christian Schnfeld Maximilian Gertler Joachim Seybold Tobias Kurth Frank P. Mockenhaupt 《Emerging infectious diseases》2021,27(7):1931
Within 5 weeks in 2021, B.1.1.7 became the dominant severe acute respiratory syndrome coronavirus 2 lineage at an outpatient testing site in Berlin, Germany. Compared with outpatients with wild-type virus infection, patients with B.1.1.7 had similar cycle threshold values, more frequent sore throat and travel history, and less frequent anosmia/ageusia. 相似文献
102.
Rataj Elisabeth Fischer Jan Bogner Andreas Försterra Beatrice Schüssler Alexandra Schütt Lukas 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2021,64(2):179-186
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Partizipation zu ermöglichen ist Teil des Auftrags der Offenen Kinder- und Jugendarbeit. Dazu gehört die Einbindung der... 相似文献
103.
Sandeep Sainathan Martha Elisabeth Heal Elman Frantz Pace Johnston Rebecca Smith Mahesh Sharma 《Indian Journal of Thoracic and Cardiovascular Surgery》2021,37(6):698
We present a case of a neonate with trisomy 21, ductal-dependent aortic coarctation, and severe respiratory failure secondary to coronavirus disease 2019 (COVID-19) pneumonia. The neonate was managed with venoarterial extracorporeal membrane oxygenation (VA ECMO), palliative stenting of the coarctation, and a vascular plug occlusion of a large patent ductus arteriosus. The patient was successfully weaned off extracorporeal membrane oxygenation (ECMO). The patient is currently awaiting a definitive surgical repair in the near future. 相似文献
104.
105.
Melody R. Palmer Daniel S. Kim David R. Crosslin Ian B. Stanaway Elisabeth A. Rosenthal David S. Carrell David J. Cronkite Adam Gordon Xiaomeng Du Yatong K. Li Marc S. Williams Chunhua Weng Qiping Feng Rongling Li Sarah A. Pendergrass Hakon Hakonarson David Fasel Sunghwan Sohn Patrick Sleiman Samuel K. Handelman Elizabeth Speliotes Iftikhar J. Kullo Eric B. Larson Gail P. Jarvik 《Genetic epidemiology》2021,45(1):4-15
106.
Demonstration of a second rapidly conducting cortico-diaphragmatic pathway in humans 总被引:5,自引:1,他引:5
Tarek Sharshar Nicholas S. Hopkinson Sophie Jonville Hélène Prigent Robert Carlier Mark J. Dayer Elisabeth B. Swallow Frédéric Lofaso John Moxham Michael I. Polkey 《The Journal of physiology》2004,560(3):897-908
Functional imaging studies in normal humans have shown that the supplementary motor area (SMA) and the primary motor cortex (PMC) are coactivated during various breathing tasks. It is not known whether a direct pathway from the SMA to the diaphragm exists, and if so what properties it has. Using transcranial magnetic stimulation (TMS) a site at the vertex, representing the diaphragm primary motor cortex, has been identified. TMS mapping revealed a second area 3 cm anterior to the vertex overlying the SMA, which had a rapidly conducting pathway to the diaphragm (mean latency 16.7 ± 2.4 ms). In comparison to the vertex, the anterior position was characterized by a higher diaphragm motor threshold, a greater proportional increase in motor-evoked potential (MEP) amplitude with voluntary facilitation and a shorter silent period. Stimulus–response curves did not differ significantly between the vertex and anterior positions. Using paired TMS, we also compared intracortical inhibition/facilitation (ICI/ICF) curves. In comparison to the vertex, the MEP elicited from the anterior position was not inhibited at short interstimulus intervals (1–5 ms) and was more facilitated at long interstimulus intervals (9–20 ms). The patterns of response were identical for the costal and crural diaphragms. We conclude that the two coil positions represent discrete areas that are likely to be the PMC and SMA, with the latter wielding a more excitatory effect on the diaphragm. 相似文献
107.
Lateral mobility and localization in the surface membrane of the adhesion molecule L1 was studied in morphologically undifferentiated and differentiated neuroblastoma cells to gain insight into its possible association with the different molecular forms of N-CAM. In undifferentiated cells, the fraction of mobile L1 molecules is high and similar to that of N-CAM 140. Upon long-term morphological differentiation, the fraction of mobile L1 molecules is reduced by a factor of three and is similar to that of N-CAM 180, the predominant molecular form of N-CAM in differentiated neuroblastoma cells. Comparable to N-CAM 180, L1 is also preferentially accumulated at contact sites between these cells as seen by indirect immunofluorescence. These observations raise the question of whether at least part of the L1 molecules may be directly or indirectly (e.g. via N-CAM 180) linked to the cytoskeleton, thus stabilizing cell contacts between differentiated cells. 相似文献
108.
Dr. M. Ruhnke A. Eigler Dr. Bettina Geiseler Dr. Elisabeth Engelmann Priv.-Doz. Dr. M. Trautmann 《Infection》1994,22(2):132-136
Summary In an open-label controlled study 23 HIV-infected patients (CDC IV A–E) with documented oropharyngeal candidosis were treated with 100 mg fluconazole orally over 5 days (53 episodes; 1–6 treatments/patient). Efficacy data were compared with a control group of 21 patients who received treatment for 10–21 days with 100 mg fluconazole for candidosis. Candida isolates were repeatedly recovered from patients before and after treatment with fluconazole and antifungal susceptibility testing (microbroth-dilution) was done. Inoculum size, medium pH, incubation time and temperature were standardized. Up to 85% of patients responded to therapy clinically and mycologically.Candida albicans was the most important yeast (86%) isolated from cultures of oral washings. In 90% ofC. albicans isolates MIC to fluconazole were low (1.56 mg/l). Primary resistance to fluconazole was not seen, but secondary resistance occurred in two cases clinically andin vitro (MIC25 mg/l). Short treatment for 5 days was as successful as for 10 to 21 days without leading to significantly more recurrences of oral candidosis in these patients. Selection ofCandida spp. other thanC. albicans (e. g.Candida krusei, Torulopsis glabrata) under repeated fluconazole treatment occurred rarely. One patient developed clinical signs of chronic recurrent candidiasis, where onlyC. krusei could be cultured repeatedly.
Korrelation zwischen MHK-Bestimmung bei Candida-Isolaten von Patienten mit HIV-Infektion und Therapieverlauf nach Behandlung mit Fluconazol
Zusammenfassung In einer offenen kontrollierten Studie wurde bei 23 HIV-infizierten Patienten (CDC IV A–E) eine dokumentierte oropharyngeale Candidose mit 100 mg Fluconazol oral über 5 Tage behandelt (53 Episoden; 1–6 Episoden/Patient). Die Ergebnisse wurden mit einer Kontrollgruppe verglichen, in der 21 HIV-infizierte Patienten über 10–21 Tage mit 100 mg Fluconazol behandelt wurden. Von den Patienten wurden vor und nach jeder Therapie mit Fluconazol Candida-Isolate gewonnen, differenziert und einer Resistenztestung unterzogen (Mikro-Dilutionstechnik). Für die Resistenztestung wurden Inokulumgröße, pH des Mediums, Inkubationszeit und -temperatur standardisiert. Bis zu 85% der Patienten zeigten klinisch und mykologisch eine Heilung/Besserung.Candida albicans war der am häufigsten isolierte Hefepilz (86%) aus sämtlichen Proben, die mit Mundspülungen gewonnen wurden. 90% allerC. albicans-Isolate warenin vitro Fluconazol-empfindlich (MHK 1,56 mg/l). Eine Primärresistenz gegenüber Fluconazol wurde nicht beobachtet, aber in zwei Fällen trat sowohl klinisch als auchin vitro eine Fluconazol-Resistenz gegenüberC. albicans auf (MHK 25 mg/l). Eine Behandlung der Candidose mit 100 mg Fluconazol über 5 Tage führte zu einer vergleichbaren Heilungs-/Besserungsrate wie über 10–21 Tage, ohne daß die Rezidivrate wesentlich erhöht war. Eine therapiebedingte Selektion von Nicht-albicans-Arten(Candida krusei, Torulopsis glabrata) nach Fluconazol-Behandlung wurde selten beobachtet. Allerdings bestand bei einem Patienten der (klinische) Verdacht auf eine durchC. krusei unterhaltende orale Candidose, da nurC. krusei wiederholt nachgewiesen werden konnte.相似文献
109.
110.
Jan Lycke Bo Svennerholm Elisabeth Hjelmquist Lars Frisén Gaby Badr Mats Andersson Anders Vahlne Oluf Andersen 《Journal of neurology》1996,243(3):214-224
Acyclovir treatment was used in a randomized, double-blind, placebo-controlled clinical trial with parallel groups to test the hypothesis that herpes virus infections are involved in the pathogenesis of multiple sclerosis (MS). Sixty patients with the relapsing-remitting form of MS were randomized to either oral treatment with 800 mg acyclovir or placebo tablets three times daily for 2 years. The clinical effect was investigated by an extensive test battery consisting of neurological examinations, neuro-ophthalmological and neuropsychological tests, and evoked potentials. Results were based on intent-to-treat data and the primary outcome measure was the exacerbation rate. In the acyclovir group (n = 30), 62 exacerbations were recorded during the treatment period, yielding an annual exacerbation rate of 1.03. The placebo group (n = 30) had 94 exacerbations and an annual exacerbation rate of 1.57. Thus, 34% fewer exacerbations were encountered during acyclovir treatment. This difference in exacerbation rate between the treatment groups was not significant (P = 0.083). However, this trend to a lower disease activity in acyclovir-treated patients was supported in subsequent data analysis. If the patients were grouped according to exacerbation frequencies, i.e. into low (0–2), medium (3–5) and high (6–8) rate groups, the difference between acyclovir and placebo treatment was significant (P = 0.017). Moreover, in a subgroup of the population with a duration of the disease of at least 2 years providing an exacerbation rate base-line before entry, individual differences in exacerbation rates were compared between the 2-year pre-study period and the study period in acyclovir-treated (n = 19) and placebo (n = 20) patients and acyclovir-treated patients showed a significant reduction of exacerbations (P = 0.024). Otherwise, neurological parameters were essentially unaffected by acyclovir treatment and there were no convincing signs of reduced neurological deterioration in the acyclovir group. This study indicates that acyclovir treatment might inhibit the triggering of MS exacerbations and thus suggests that acyclovir-susceptible viruses might be involved in the pathogenesis of MS. This possibility warrants further investigation. 相似文献